



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,135	06/09/2005	Maosheng Duan	PU5020USw	5458
23347	7590	06/05/2008		
GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B482 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398			EXAMINER MABRY, JOHN	
			ART UNIT 1625	PAPER NUMBER
			NOTIFICATION DATE 06/05/2008	DELIVERY MODE ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USCIPRTP@GSK.COM  
LAURA.M.MCCULLEN@GSK.COM  
JULIE.D.MCFALLS@GSK.COM

<b>Office Action Summary</b>	<b>Application No.</b> 10/538,135	<b>Applicant(s)</b> DUAN ET AL.	
	<b>Examiner</b> John Mabry, PhD	<b>Art Unit</b> 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 09 June 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-39 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-39 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### DETAILED ACTION

Applicant is respectfully reminded that it is required that all claims be amended to elected group. Examiner also warns Applicant not to introduce new matter when amending.


### *Election/Restrictions*

Restriction is required under 35 U.S.C. 121 and 372.


This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1-8, 11-21, 28 and 34-36 are drawn to compounds and pharmaceutical

compositions of Formula I, wherein R10=phenyl, X=alkyl, A= , piperidinyl, R1=-N-R9-(Y)m-R3 wherein R9 is alkyl, Y=-C(O)- and R3 is independently selected. A further election of single disclosed species is required.

- II. Claims 1-4, 9, 11-22, 28 and 34-36 are drawn to compounds and pharmaceutical

compositions of Formula I, wherein R10=phenyl, X=alkyl, A= , piperidinyl, R1=-N-R9-(Y)m-R3 wherein (Y)m- and R9 is combine with nitrogen to

Art Unit: 1625

which they are attached to form a ring. A further election of single disclosed species is required.

- III. Claims 1-8, 11-21, 28 and 34-36 are drawn to compounds and pharmaceutical compositions of Formula I, wherein R10=phenyl, X=alkyl, A= piperidinyl, R1=-N-R9-(Y)m-R3 wherein R9 is alkyl, Y=-C(O)- and R3 is independently selected. A further election of single disclosed species is required.
- IV. Claims 1-4, 9, 11-22, 28 and 34-36 are drawn to compounds and pharmaceutical compositions of Formula I, wherein R10=phenyl, X=alkyl, A= piperidinyl, R1=-N-R9-(Y)m-R3 wherein (Y)m- and R9 is combine with nitrogen to which they are attached to form a ring. A further election of single disclosed species is required.
- V. Claims 1-28 and 34-36 are drawn to compounds and pharmaceutical compositions of Formula I that are not encompassed by Groups I-IV. A further election of single disclosed species is required. This group may be subject to further restriction.
- VI. Claims 23-24 and 37-39 are drawn to a method of treatment of a viral infection limited to scope of one of groups I-III. If this group is elected, a further election of a single disclosed therapeutic agent is also required. An election of species is required if this group is chosen. Further restriction may be required.

- VII. Claims 25-26 are drawn to a method of treatment of a bacterial infection limited to scope of one of groups I-III. An election of species is required if this group is chosen.
- VIII. Claims 27 are drawn to a method of treating diseases and disorders as described by Applicant using one of groups I-V. An election of species is required if this group is chosen.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features...those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.


The special technical feature corresponding to Group I is a structure of Formula I, wherein R10=phenyl, X=alkyl, A= tropanyl, piperidinyl, R1=-N-R9-(Y)m-R3 wherein R9 is alkyl, Y=-C(O)- and R3 is independently selected. Group II contains a structure of Formula I as its special technical feature, wherein R10=phenyl, X=alkyl, A=tropanyl, piperidinyl, R1=-N-R9-(Y)m-R3 wherein (Y)m- and R9 is combine with nitrogen to which they are attached to form a ring. The special technical feature corresponding to Group III is a structure of Formula I, wherein R10=phenyl, X=alkyl, A= piperidinyl, R1=-N-R9-

Art Unit: 1625

(Y)<sub>m</sub>-R<sub>3</sub> wherein R<sub>9</sub> is alkyl, Y=-C(O)- and R<sub>3</sub> is independently selected. Group IV contains a structure of Formula I as its special technical feature, wherein R<sub>10</sub>=phenyl, X=alkyl, A= piperidinyl, R<sub>1</sub>=-N-R<sub>9</sub>-(Y)<sub>m</sub>-R<sub>3</sub> wherein (Y)<sub>m</sub>- and R<sub>9</sub> is combine with nitrogen to which they are attached to form a ring. Group V contains a structure of Formula I as its special technical feature that are not encompassed by Groups I or II. The ring systems are not considered equivalent.


The technical feature corresponding to the methods claims of Groups VI, VII and VIII are: method of treatment of a viral infection limited to scope of one of groups I-V, a method of treatment of a bacterial infection limited to scope of one of groups I-V and a method of treating a list of diseases/disorders as described by Applicant - found in the individual compound and composition groups above. There is a significant difference in the between compounds/composition and methods of treating a viral infections, bacterial infections and a method of treatment of disease/condition. These treatments of diseases/conditions and compounds/compositions are not considered equivalent.

The special technical feature of this invention is the common core found in Formula I. This special technical feature, found in WO 97/09308 as described by Britton et al (Example 273, page 278) (PTO-1449).



The claimed genus of Formula I, as described in claim 1, is very broad and expansive. In Examiner's attempt to break unity as required for the restriction, the preliminary search results were so numerous that the STN Search did not go to completion. This presents an undue burden on the Examiner. The results below serve as proof. The scope of the claimed invention is so expansive that the STN Search was not able to complete its search and exceeded the systems limit. Several attempts were also made to select a subgenus of Applicants' invention which still resulted in an incomplete search which exceeded the system's limit.

Art Unit: 1625



Structure attributes must be viewed using STN Express query preparation.

=> s 121 sss sam

SAMPLE SEARCH INITIATED 10:06:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 257765 TO ITERATE

0.8% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 5125667 TO 5184933  
PROJECTED ANSWERS: 0 TO 0

Therefore the above claims, are not so linked as to form a single general inventive concept and there is a lack of unity of invention because they lack a common core structure and the technical features present fail to define a contribution over the prior art. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper.

Therefore, since the claims do not relate to a single general inventive concept under PCT Rule 13.1 and lack the same or corresponding special technical features, the claims lack unity of invention and should be limited to only one invention.



Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

**Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.**

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly

and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not

distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

### ***Rejoinder Advisory***

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product

claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### ***Conclusion***

Applicant is respectfully reminded that it is required that all claims be amended to elected group. Examiner also warns Applicant not to introduce new matter when amending.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Mabry, PhD whose telephone number is (571) 270-1967. The examiner can normally be reached on M-F from 9am to 5pm.

Art Unit: 1625

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, PhD, can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/John Mabry, PhD/  
Examiner  
Art Unit 1625

/Rita J. Desai/  
Primary Examiner, Art Unit 1625